Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination With Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects With FIGO Stage IVB or Recurrent or Persistent Cervical Cancer With Zero or One Prior Chemotherapy Regimen

This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer

Study Overview

• Status: Completed
• Conditions: Metastatic Cervical Cancer; Neoplasms, Uterine Cervix
• Intervention / Treatment: Drug: lapatinib (GW572016); Drug: pazopanib (GW786034)

Detailed Description

A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects with International Federation of Gynecology (FIGO) Stage IVB or Recurrent or Persistent Cervical Cancer with Zero or One Prior Chemotherapy Regimen for Advanced/Recurrent Disease

• Study Type: Interventional
• Enrollment (Actual): 228
• Phase: Phase 2

Contacts and Locations

Study Locations

• Argentina
  • Quilmes, Argentina, 1878
    • GSK Investigational Site
  • Santa Fe, Argentina, 3000
    • GSK Investigational Site
  • Buenos Aires
    • Capital Federal, Buenos Aires, Argentina, C1405CUB
      • GSK Investigational Site
    • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1185AAT
      • GSK Investigational Site
  • Neuquén
    • Neuquen, Neuquén, Argentina, Q8300HDH
      • GSK Investigational Site
  • Santa Fe
    • Rosario, Santa Fe, Argentina, S2000KZE
      • GSK Investigational Site
  • Tucumán.
    • Tucuman, Tucumán., Argentina, 4000
      • GSK Investigational Site
• Belgium
  • Brussel, Belgium, 1000
    • GSK Investigational Site
  • Bruxelles, Belgium, 1200
    • GSK Investigational Site
  • Gent, Belgium, 9000
    • GSK Investigational Site
  • Leuven, Belgium, 3000
    • GSK Investigational Site
  • Roeselare, Belgium, 8800
    • GSK Investigational Site
• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2N 4N2
      • GSK Investigational Site
  • British Columbia
    • Vancouver, British Columbia, Canada, V5Z 4E6
      • GSK Investigational Site
  • Ontario
    • Hamilton, Ontario, Canada, L8V 5C2
      • GSK Investigational Site
    • Toronto, Ontario, Canada, M5G 2M9
      • GSK Investigational Site
  • Quebec
    • Montréal, Quebec, Canada, H2L 4M1
      • GSK Investigational Site
• Estonia
  • Tallinn, Estonia, 11619
    • GSK Investigational Site
  • Tartu, Estonia, 51003
    • GSK Investigational Site
• France
  • Bordeaux, France, 33076
    • GSK Investigational Site
  • Caen Cedex, France, 14076
    • GSK Investigational Site
  • Lille Cedex, France, 59020
    • GSK Investigational Site
  • Marseille Cedex 09, France, 13273
    • GSK Investigational Site
  • Strasbourg, France, 67085
    • GSK Investigational Site
  • Villejuif, France, 94805
    • GSK Investigational Site
• Germany
  • Berlin, Germany, 10367
    • GSK Investigational Site
  • Berlin, Germany, 10117
    • GSK Investigational Site
  • Bayern
    • Muenchen, Bayern, Germany, 80337
      • GSK Investigational Site
  • Saarland
    • Saarbruecken, Saarland, Germany, 66113
      • GSK Investigational Site
  • Sachsen-Anhalt
    • Halle, Sachsen-Anhalt, Germany, 06120
      • GSK Investigational Site
    • Magdeburg, Sachsen-Anhalt, Germany, 39108
      • GSK Investigational Site
• India
  • Ahemdabad, India, 380016
    • GSK Investigational Site
  • Mangalore, India, 575001
    • GSK Investigational Site
  • New Delhi, India, 110096
    • GSK Investigational Site
  • Trivandrum, India, 695011
    • GSK Investigational Site
• Ireland
  • Cork, Ireland
    • GSK Investigational Site
  • Dublin, Ireland, 7
    • GSK Investigational Site
• Italy
  • Campania
    • Napoli, Campania, Italy, 80131
      • GSK Investigational Site
  • Lombardia
    • Milano, Lombardia, Italy, 20141
      • GSK Investigational Site
  • Molise
    • Campobasso, Molise, Italy, 86100
      • GSK Investigational Site
  • Puglia
    • Bari, Puglia, Italy, 70124
      • GSK Investigational Site
• Mexico
  • Mexico City, Mexico, CP 14080
    • GSK Investigational Site
• Spain
  • Barcelona, Spain, 08036
    • GSK Investigational Site
  • Barcelona, Spain, 08907
    • GSK Investigational Site
  • La Laguna (Santa Cruz de Tenerife), Spain, 38320
    • GSK Investigational Site
  • Madrid, Spain, 28007
    • GSK Investigational Site
  • Marid, Spain, 28040
    • GSK Investigational Site
  • Pamplona, Spain, 31008
    • GSK Investigational Site
• Thailand
  • Bangkok, Thailand, 10330
    • GSK Investigational Site
  • Chiang Mai, Thailand, 50200
    • GSK Investigational Site
  • Khon Kaen, Thailand, 40002
    • GSK Investigational Site
• United States
  • California
    • Los Angeles, California, United States, 90033
      • GSK Investigational Site
    • Orange, California, United States, 92868
      • GSK Investigational Site
    • Stanford, California, United States, 94305-5317
      • GSK Investigational Site
  • Georgia
    • Augusta, Georgia, United States, 30912
      • GSK Investigational Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02115
      • GSK Investigational Site
  • New Mexico
    • Albuquerque, New Mexico, United States, 87131-5276
      • GSK Investigational Site
  • New York
    • New York, New York, United States, 10016
      • GSK Investigational Site
  • Ohio
    • Cleveland, Ohio, United States, 44106
      • GSK Investigational Site
    • Columbus, Ohio, United States, 43214
      • GSK Investigational Site
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
      • GSK Investigational Site
  • Tennessee
    • Chattanooga, Tennessee, United States, 37403
      • GSK Investigational Site
  • Texas
    • Dallas, Texas, United States, 75390
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• A subject will be eligible for inclusion in this study only if all of the following criteria are met:
• Signed, written informed consent prior to performing any study-related procedures
• Female subjects ≥18 years of age
• FIGO Stage IVB, or recurrent or persistent cervical cancer
• Life expectancy of at least 12 weeks
• ECOG status of 0 or 1.
• Histologically confirmed FIGO Stage IVB, or recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy
• Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be ≥ 20 mm when measured by conventional techniques, including palpitation, plain x-ray, CT and MRI, or ≥10 mm when measured by spiral CT.
• At least one "target lesion" to be used to assess response as defined by Response Evaluation Criteria in Solid Tumors (RECIST; Terasse, 2000). Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy.
• Received 0 or 1 prior chemotherapy regimen for metastatic disease.
• Note: Chemotherapy given in combination with radiation therapy as a radiosensitizer does not count toward this prior therapy limit
• Recovered from the effects of surgery or chemotherapy. At least three weeks must have elapsed from the last administration of chemotherapy.
• Adequate organ and bone marrow function as defined in Table 1.
• Table 1:(Definitions for Adequate Organ Function)
• System:(Laboratory Values)
• Hematologic: Absolute neutrophil count (ANC)(≥ 1.5 X 109/L)Hemoglobin1(≥9 g/dL)Platelets(≥100 X 109/L)
• Hepatic: Total bilirubin (≤1.5 X ULN)AST and ALT (≤2.5 X ULN)
• Renal: Calculated creatinine clearance2 (≥50 mL/min)
• Urine protein3 (Negative, trace or +1 by dipstick urinalysis or <1.0 gram determined by 24 hour urine protein analysis.)
• Subjects may not have had a transfusion within 7 days of screening assessment.
• Calculated by Cockcroft Gault formula See Appendix 7: Renal Function Tests
• A patient should first be screened with dipstick urinalysis. If urine protein by dipstick analysis is ≥2+, then a 24-hour urine protein must be assessed and 24 hour urine protein must be <1 g protein to be eligible.
• Ability to swallow and retain oral medication.
• A female is eligible to enter and participate in this study if she is of:
• Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had:
• A hysterectomy
• A bilateral oophorectomy (ovariectomy)
• A bilateral tubal ligation
• Is post-menopausal (total cessation of menses for ≥ 1 year)
• Childbearing potential, has a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception. GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows:
• An intrauterine device with a documented failure rate of less than 1% per year.
• Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.
• Complete abstinence from sexual intercourse for 14 days before exposure to investigation product, through the dosing period, and for at least 21 days after the last dose of investigational product.
• Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide).

Note: Oral contraceptives are not reliable due to potential drug-drug interactions.

• Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow-up as outlined in the protocol. Procedures conducted as apart of routine clinical management of the patient (e.g., blood count, imaging study) and obtained prior to signed informed consent may be utilized for screening purposes provided these tests are obtained as specified in the protocol

Exclusion Criteria:

• A subject will not be eligible for inclusion in this study if any of the following criteria apply:
• Neuroendocrine or small cell carcinoma of the cervix.
• Prior use of any biologic therapy with VEGF, VEGFR, or ErbB1/ErbB2 inhibitors.
• Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization).
• Concurrent treatment with an investigational agent or participation in another clinical trial.
• Use of an investigational anti-cancer drug within 28 days or 5 half-lives, whichever is longer, preceding the first dose of study medication.
• Has taken or is taking prohibited medications listed in the protocol.
• Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with patient's safety, obtaining informed consent or compliance to the study.
• History of another malignancy. Note: Patients who have had another malignancy and have been disease-free for 5 years, or patients with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.
• History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis. Routine screening with CNS imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated.
• Malabsorption Syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.
• Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to beginning therapy.
• Presence of uncontrolled infection.
• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib.
• Corrected QT interval (QTc) prolongation defined as QTc interval > 470 msecs.
• History of any one of the following cardiac conditions within the past 6 months:
• Cardiac angioplasty or stenting
• Myocardial infarction
• Unstable angina
• History of cerebrovascular accident or pulmonary embolus within the past 6 months.
• Has Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system (See Appendix 6)
• Poorly controlled hypertension (systolic blood pressure (SBP) of ≥ 140mmHg, or diastolic blood pressure (DBP) of ≥ 90mmHg).
• Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. The blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 24 hours. The mean SBP/DBP values from both BP assessments must be < 140/90mmHg in order for a subject to be eligible for the study.
• History of untreated deep venous thrombosis (DVT) within the past 6 months (e.g. calf vein thrombosis).
• Note: Patients with recent DVT who are treated with therapeutic anti-coagulant agents (excluding therapeutic warfarin) for at least 6 weeks are eligible.
• Presence of any non-healing, non-tumor related wound, fracture, or ulcer, or the presence of symptomatic peripheral vascular disease.
• Subjects with bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage.
• Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to beginning therapy, or anticipation of the need for a major surgical procedure during the course of the study; minor surgical procedures such as fine needle aspiration or core biopsy within 1 week prior to beginning therapy are also excluded.
• Unable to swallow and retain orally administered medication.
• Pregnant or lactating female.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Combination arm; Pazopanib plus lapatinib	Drug: lapatinib (GW572016)
Active Comparator: Lapatinib monotherapy; Lapatinib	Drug: lapatinib (GW572016)
Active Comparator: Pazopanib monotherapy; Pazopanib	Drug: pazopanib (GW786034)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free Survival (PFS) in Interim Analysis	PFS is defined as the interval between the date of randomization and the date of disease progression or death due to any cause. The study was designed to test Combination vs. Lapatinib first. The result indicated that Combination would not show improvement over Lapatinib even if followed until the final analysis and the Combination arm was terminated. The monotherapy arms continued to the final analysis. Data shown here are from this interim analysis.	From randomization until at least 35 PFS events in pairwise comparison of the three treatment arms (Interim Analysis; up to 52.14 weeks)
Progression-free Survival (PFS) in Final Analysis	PFS is defined as the interval between the date of randomization and the date of disease progression or death due to any cause. This study began as a 3-arm study. The combination arm was terminated at the interim analysis. The monotherapy arms continued to final analysis. Data shown here are from the final analysis.	From Randomization until 105 total PFS events in combined population of two monotherapy arms (up to 85.57 weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival	Overall survival is defined as the time from randomization until death due to any cause.	From Randomization (11 December 2006) until approximately 78% overall survival events at the time of the second overall survival update (3 March 2010) (up to 168.29 weeks)
Clinical Benefit Response	Clinical benefit response is defined as the number of participants with evidence of complete (CR) or partial (PR) tumor response or stable disease (SD) for at least 6 months (183 days). Per Response Evaluation Criteria In Solid Tumors (RECIST): CR, all detectable tumor has disappeared; PR, a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum; Stable Disease, small changes that do not meet previously given criteria. Confirmation requires at least 2 assessments of CR/PR with at least 4 weeks between assessments.	From Randomization until 105 total PFS events in combined population of two monotherapy arms (up to 85.57 weeks)
Response	Response is defined as the number of participants achieving either a complete or partial tumor response per RECIST criteria. CR, all detectable tumor has disappeared; PR, a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum.	From Randomization until 105 total PFS events in combined population of two monotherapy arms (up to 85.57 weeks)
Time to Response	For the subset of participants who showed a confirmed CR or PR, time to response was defined as the time from randomization until the first documented evidence of CR or PR (whichever status was recorded first). CR, all detectable tumor has disappeared; PR, a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum.	From Randomization until 105 total PFS events in combined population of two monotherapy arms (up to 85.57 weeks)
Duration of Response	For participants who had a CR or PR, the duration of response was defined as the time from first documented evidence of PR or CR until the first documented sign of disease progression or death. CR, all detectable tumor has disappeared; PR, a >=30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum.	From Randomization until 105 total PFS events in combined population of two monotherapy arms (up to 85.57 weeks)
Safety and Tolerability of Pazopanib, Lapatinib and the Combination of Pazopanib and Lapatinib	Safety was assessed as the number of participants experiencing a serious adverse event (SAE) or an adverse event (AE). See the adverse event module for safety data.	From Randomization (11 December 2006) until last participant had last visit (28 July 2011) in combined population of two monotherapy arms (up to 241.43 weeks)

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• de Jonge MJ, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J, Arumugham T, Pandite LN, Hurwitz HI. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs. 2013 Jun;31(3):751-9. doi: 10.1007/s10637-012-9885-8. Epub 2012 Oct 6.
• Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts MW, Pandite LN. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010 Aug 1;28(22):3562-9. doi: 10.1200/JCO.2009.26.9571. Epub 2010 Jul 6.
• Monk BJ, Pandite LN. Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2011 Dec 20;29(36):4845. doi: 10.1200/JCO.2011.38.8777. Epub 2011 Nov 14. No abstract available.

Study record dates

Study Major Dates

• Study Start: November 1, 2006
• Primary Completion (Actual): July 1, 2008
• Study Completion (Actual): July 1, 2011

Study Registration Dates

• First Submitted: January 31, 2007
• First Submitted That Met QC Criteria: February 1, 2007
• First Posted (Estimate): February 2, 2007

Study Record Updates

• Last Update Posted (Estimate): May 8, 2015
• Last Update Submitted That Met QC Criteria: April 15, 2015
• Last Verified: April 1, 2015

More Information

Terms related to this study

• Keywords: VEGF; lapatinib; advanced; persistent; recurrent; pazopanib; metastatic cervical cancer; ErB1/ErB2; FIGO Stage IVB
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Genital Neoplasms, Female; Uterine Cervical Diseases; Uterine Diseases; Uterine Cervical Neoplasms; Uterine Neoplasms; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Protein Kinase Inhibitors; Lapatinib
• Other Study ID Numbers: VEG105281